Cantor Fitzgerald reiterates Overweight on Solid Biosciences stock
At a glance
- $SLDB today−3.86%last $6.23
- Vs industry peers−4.17 pts6-peer median +0.31% · far behind
- Since Sep 16−28.6%from the first trade after the story
- 52-week range46.9% above low$4.24 – $11.45
- Cash runway~8 mo$126.0M cash ÷ $16.2M/mo burn · 10-Q
- Sector scannerCalmHealth Care
Nothing reported about solid biosciences across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Policy moves the whole healthcare aisle; trial data moves one company. Knowing which kind of story this is helps.
- How the stock is trading: $SLDB -3.86% in the latest session.
- Timing: It was published before the opening bell, so the next session was the first chance to trade on it.
Where the stock stands
Solid Biosciences ($SLDB) fell 3.86% to $6.23 in the latest session. Over the past month it is up 5.8%. It now sits 46% under the 52-week high of $11.45 and 47% above the year's low of $4.24. The year's high was 2.7 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 4, 2026), $SLDB lost $53.9M over the quarter to Sep 30, 2026. Operations used $145.4M of cash over the nine months to Sep 30, 2026 — about $16.2M a month — against $126.0M in cash on Sep 30, 2026. At that pace the cash covers about 8 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $47.8M against $126.0M of cash on Sep 30, 2026. Its most recent filings before this story: 8-K on Aug 6, 2026, 10-Q on Aug 6, 2026, 8-K on Jun 10, 2026. Figures are as filed with the SEC; the $SLDB page has the full statements.
How much coverage it is getting
Nothing new on Solid Biosciences has come through Wook's feeds in the last 30 days, so this is still the most recent story on it.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $SLDB page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $SLDB: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on September 16, 2026. $SLDB has moved -28.56% ($8.72 to $6.23). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
